Novartis Pharmaceuticals
East Hanover, New Jersey, United States
NCT Number: NCT00219063
To compare the aliskiren regimen versus the ramipril regimen on reduction in Blood Pressure.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
East Hanover, New Jersey, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Novartis
Industry
A 26 Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing Aliskiren to Ramipril With Optional Addition of Hydrochlorothiazide, Followed by a 4 Week Double-blind, Randomized, Placebo-controlled Withdrawal in Patients With Essential Hypertension
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02055209
Cardiovascular Diseases, Hypertension
Bethesda, Maryland, United States
View Trial DetailsNCT02692846
Aortic Stenosis, Supravalvular, Aortic Valve Disease
Bethesda, Maryland, United States
View Trial DetailsNCT07747363
Cardiovascular Diseases, Chronic Disease
Austin, Texas, United States
View Trial DetailsNCT07432893
Body Temperature Changes, Breathlessness
Birbhum, West Bengal, India
View Trial Details